ROCKVILLE, Md., Oct. 29 /PRNewswire/ -- BioReliance Corporation today appointed its Executive Chairman, Charles C. Harwood, Jr., to the additional post of Interim CEO, following the announced resignation of Tim Derrington from the CEO position. In addition, BioReliance announced that three senior executives have joined the company since June: David E. Onions, Ph.D., as Chief Scientific Officer, David S. Walker as Chief Financial Officer, and Darryl L. Goss as Vice President of Global Process Excellence.
BioReliance is a portfolio company of Avista Capital Partners and was purchased in April 2007 from Invitrogen Corporation. Charles Harwood comments, "While Tim Derrington's personal decision to leave BioReliance was not anticipated at the time of the acquisition, the Board does not believe it will affect the timetable for strengthening the senior executive team and setting a clear course for BioReliance as a stand-alone company."
In addition to serving as Executive Chairman of BioReliance, Mr. Harwood serves on the boards of several other healthcare companies, including ATCC and RadPharm, Inc., and recently formalized a relationship with Avista to support their healthcare team as a Healthcare Industry Advisor. From 2002 to 2006, Mr. Harwood served as President and CEO of Focus Diagnostics, Inc., a specialty diagnostics company offering advanced laboratory testing services and diagnostic products. Previously, from 1993 to 2001, Mr. Harwood held several positions, including Chief Financial Officer and SVP of Venture Development, at Covance, Inc., one of the largest drug development services companies. Mr. Harwood began his healthcare career in the medical equipment field working for the Medical Products Group of Hewlett-Packard Company. He received an MBA from Harvard Business School and a Bachelor of Arts from Stanford University.
David Onions is the Chief Scientific Officer and a member of the Board of BioReliance. He was formerly Chief Medical Officer of Invitrogen and before that Director of the Leukaemia Research Fund's Virus Centre and Professor of Veterinary Virology at the University of Glasgow. Dr. Onions was a founding director of Q-One Biotech which was acquired by BioReliance in 2003. He is a member, or former member, of several advisory groups including the FDA's Xenotransplantation Advisory Committee and the World Health Organisation's Expert Advisory Panel on Biological Standardization. Dr. Onions is a Fellow of the Royal Society of Edinburgh, Fellow of the Academy of Medical Sciences, and a Fellow of the Royal Society of Arts.
David Walker serves as the Chief Financial Officer of BioReliance. Previously, Mr. Walker was the CFO of American Type Culture Collection, or ATCC. From 2003 to 2006, Mr. Walker was the VP and CFO of Focus Diagnostics. He served as SVP and CFO of Restoragen, Inc. from 2000 to 2003. Prior to 2000, Mr. Walker held various senior finance positions with Arbor Acres, Inc., Fisons plc, and The Boots Company, plc. Mr. Walker graduated from Nottingham Trent University in Nottingham, England, with a degree in Accounting and Finance and is a qualified member of the Chartered Institute of Management Accountants in England.
Darryl Goss has joined BioReliance as the VP of Global Process Excellence. Prior to joining BioReliance, Mr. Goss was SVP and Chief Operating Officer of Esoterix, Inc. following its acquisition by LabCorp. From 2000 to 2005, he held a variety of other senior executive roles at Esoterix including SVP of Business Operations and Chief Information Officer. From 1993 to 2000, Mr. Goss worked at Covance Central Laboratory Services, Inc., serving in such roles as VP of Information Technology & Services. Prior to 1993, he held various information technology and business development positions with Smith Kline Beecham Clinical Laboratories, Guidance Opportunity, Inc., Beatrice Hunt-Wesson and IBM. Mr. Goss has a Masters of Business Administration from the University of Chicago and completed post-graduate work in Advanced Management from Oxford University in Oxford, England. In addition, Mr. Goss graduated from the University of California Davis with a Bachelor of Arts.
BioReliance Corporation is a leading contract services organization, offering more than 1,000 tests or services related to biologics safety testing, in vitro and in vivo toxicology, viral manufacturing and lab animal health diagnostics for the biopharmaceutical and pharmaceutical industries. BioReliance has its primary facilities in Rockville, Maryland; Glasgow, Scotland; and Stirling, Scotland. Headquartered in Rockville, Maryland, BioReliance employs over 700 people globally. For more information, visit http://www.bioreliance.com.
David Walker, BioReliance, 301-610-2866, email@example.com
|SOURCE BioReliance Corporation|
Copyright©2007 PR Newswire.
All rights reserved